Serotonin receptors 5-HT1B and 5-HT1D in the
cerebral arteries are activated by the 5-hydroxytryptophan agonists (triptans)
to relieve the discomfort associated with migraines. Even though triptans are
often used to treat acute migraines, there is some debate over their
effectiveness.
The present study evaluated the effectiveness of
triptans for acute treatment of migraine in young individuals by searching the
reputed databases. It identified 1047 studies and finally included 25 articles
in the study.
The study observed-
This study found rizatriptan (good tolerability profile with a dose of 5 mg) and sumatriptan (nasal spray, 10 mg, and 20 mg) to be more efficient than other triptans. Regardless of type or dose, patients generally well tolerate all triptans, but a few adverse effects, such as light-headedness (sumatriptan), nasopharyngitis, and muscular spasms (sumatriptan/ naproxen), somnolence, and dry mouth (rizatriptan), and dizziness (zolmitriptan group) may be associated with the triptans.
Chanchlani R, Agrawal A, Janjua D. et al. The
Efficacy of Different Triptans for the Treatment of Acute Headache in Pediatric
Migraine: A Systematic Review. Indian Pediatr.2023; 60:663–671.
https://doi.org/10.1007/s13312-023-2968-0
Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.
Please login to comment on this article